Clinical efficacy of WYHZ formula on maternal-fetal interface microenvironment and embryo implantation in patients with chronic endometritis combined with recurrent implantation failure

试验速览

阶段: 1 期
状态: 招募中
发起方: First Teaching Hospital of Tianjin University of Traditional Chinese Medicine

暂无简介。

•1) Be between the ages of 25-40 years.
•2) meeting the diagnostic criteria for CE and RIF.
•3) TCM evidence consistent with spleen and kidney yang deficiency and internal dampness.
•4) having transferable D3-day high-quality frozen embryos (7-9 embryonic cells on day 3 after fertilization, 10% fragmentation, with stage-stage specific cell size and no multinucleation) or frozen blastocysts (=3BB).
•5) estrogen and progestin replacement therapy (HRT) with an endometrial thickness of =7 mm on the day of endometrial transformation.
•6) voluntarily subjected to the trial and agreed to sign the informed consent form.

•1) Those who are ready to undergo PGD.
•2) Those receiving donor eggs.
•3) chromosomal abnormalities (excluding chromosomal polymorphisms) in both or one of the spouses.
•4) Patients with known embryonic factors leading to implantation failure.
•5) uterine pathologies that may affect implantation (including uterine malformations, uterine tuberculosis, history of uterine adhesions, submucosal fibroids, adenomyosis, >4 cm interstitial myomas)
•6) recurrent spontaneous abortion (2 or more fetal losses before 28 weeks of gestation)
•7) combined with other endocrine disorders such as thyroid disease, hyperprolactinemia, insulin resistance, diabetes mellitus, adrenal disease, etc., with poorly controlled hormone levels in the last 3 months
•(8) clearly diagnosed autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, antiphospholipid syndrome, etc.
•9) those with untreated hydrocele in the fallopian tubes
•10) Those who are allergic to the drugs in this study.

发起方